Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopep Allsino Bio Pharmaceutical Co's quarterly Total Liabilities
increased
from Sep. 2025 (¥3,555.93 Mil) to Dec. 2025 (¥3,738.59 Mil) but then
declined
from Dec. 2025 (¥3,738.59 Mil) to Mar. 2026 (¥3,686.46 Mil).
Sinopep Allsino Bio Pharmaceutical Co's annual Total Liabilities
increased
from Dec. 2023 (¥1,357.94 Mil) to Dec. 2024 (¥2,395.70 Mil) and
increased
from Dec. 2024 (¥2,395.70 Mil) to Dec. 2025 (¥3,738.59 Mil).
Sinopep Allsino Bio Pharmaceutical Co Total Liabilities Related Terms
Sinopep Allsino Bio Pharmaceutical Co Total Liabilities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co Total Liabilities Chart
Sinopep Allsino Bio Pharmaceutical Co Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) has a Total Liabilities of ¥3,686 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sinopep Allsino Bio Pharmaceutical Co and its competitors.
Is Sinopep Allsino Bio Pharmaceutical Co's Total Liabilities too high?
Sinopep Allsino Bio Pharmaceutical Co's current Total Liabilities is ¥3,686 Mil. Overall, Sinopep Allsino Bio Pharmaceutical Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopep Allsino Bio Pharmaceutical Co's Total Liabilities compare to VRTX and REGN?
Sinopep Allsino Bio Pharmaceutical Co's Total Liabilities of ¥3,686 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Sinopep Allsino Bio Pharmaceutical Co and its competitors. Sinopep Allsino Bio Pharmaceutical Co's current Total Liabilities is ¥3,686 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopep Allsino Bio Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥58.87, compared to a current price of ¥28.00 — trading 52.4% below its estimated fair value. The current Total Liabilities is ¥3,686 Mil. Sinopep Allsino Bio Pharmaceutical Co's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076), the current Total Liabilities is ¥3,686 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopep Allsino Bio Pharmaceutical Co (SHSE:688076) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopep Allsino Bio Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥28.00 is trading 52.4% below its estimated GF Value™ of ¥58.87.
GuruFocus considers Sinopep Allsino Bio Pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for SHSE:688076:
Total Liabilities: ¥3,686 Mil
GF Value™: ¥58.87 vs. price of ¥28.00 (52.4% below fair value)
No single metric tells the full story. See the SHSE:688076 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopep Allsino Bio Pharmaceutical Co Business Description
Sinopep Allsino Bio Pharmaceutical Co Ltd is a market-oriented, research and development and innovation-driven biomedical enterprise focusing on the research, development, production and sales of peptide drugs and small molecule chemical drugs.
65GF Score
Get the complete analysis for SHSE:688076
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688076 has been successfully added to your 
